Fetal stem cells could revolutionize diabetes care

NCT ID NCT07495956

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment using clonal fetal mesenchymal stem cells (cfMSCs) for people with type 2 diabetes. The goal is to see if it is safe and can improve blood sugar control. Thirty adults with poorly controlled diabetes will receive the stem cell therapy and be monitored for side effects and changes in blood sugar levels over 24 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: clonal fetal mesenchymal stem cells
What this could lead to: If it works, this could lead to a new way to manage type 2 diabetes by improving blood sugar control and reducing the need for daily medications.
What could go wrong: This is an early phase 1/2 trial with only 30 participants, so results are preliminary. Stem cell therapies can have unknown side effects, and the long-term safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE II DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE II DIABETES MELLITUS

Contacts and locations

Locations

Shenzhen Geno-immune Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.